Australian industry has a vital role to play in the COVID-19 response, with regard to both developing novel solutions and consolidating supply chain strength in the face of this and potential future pandemic threats. Australian industry has a critical role in ensuring supply of essential therapeutics and active pharmaceutical ingredients for vaccine and drug development. (more…)Posted by Harry Baxter on October 7th, 2020 Tagged: collaboration, Countermeasures, DMTC, DST, innovation, MCM
The challenge to develop a safe, effective and low-cost universal malaria vaccine is being tackled by a DMTC collaboration with James Cook University’s Australian Institute of Tropical Health Medicine (AITHM), Townsville Hospital, Glycosyn and Pfizer Hospira. (more…)Posted by Harry Baxter on September 4th, 2020 Tagged: collaboration, DMTC, innovation, MCM, technology
DMTC Program Leader Dr Felicia Pradera joined Defence Connect host Phil Tarrant for a wide-ranging discussion on the development of technologies and industrial capabilities that will enhance Australia’s preparedness to deal with emerging pandemic disease threats. (more…)Posted by Harry Baxter on September 19th, 2019 Tagged: collaboration, Countermeasures, CSIRO, defence technology, DMTC, DST, MCM
DMTC industry partner Anteo Diagnostics Ltd has notified the ASX of the successful completion of the first milestone in their DMTC project, with initial studies demonstrating high-detection sensitivity.
Anteo has partnered with Planet Innovation, Deakin University and DMTC to further the technology readiness of Planet Innovation’s (Nplex) low cost, high sensitivity point of care diagnostic system using breakthrough reader technology.
Anteo’s contribution and objectives in Milestone 1 were to successfully functionalise nanoparticles requiring integration with Planet Innovation’s reader. Anteo has successfully established, optimised and verified a model lateral flow system for the nominated target assay using Mix&Go.
Work on the next milestone is already underway and is scheduled to be completed by next quarter.
The DMTC Medical Countermeasures (MCM) program recognises the increasingly important need to create, in Australia, an integrated multidisciplinary network focused on MCM product development.
Anteo’s statement is available here.Posted by Harry Baxter on April 21st, 2017 Tagged: DMTC, MCM, research